Dr. Olek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
701 Gateway Blvd
Suite 420
South San Francisco, CA 94080
Education & Training
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1991 - 1994
Philadelphia College of Osteopathic MedicineClass of 1991
Certifications & Licensure
VA State License 1992 - 2026
MA State License 1994 - 2025
PA State License 1987 - 1998
Clinical Trials
- An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment Start of enrollment: 2008 May 01
Publications & Presentations
PubMed
- 71 citationsOvercoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinibEzra Y. Rosen, Melissa Lynne Johnson, Sarah E. Clifford, Romel Somwar, Jennifer Kherani
Clinical Cancer Research. 2021-01-01 - 5 citationsThe calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.Taras Lysyy, Alshad S. Lalani, Elizabeth A. Olek, Irmina Diala, John P. Geibel
Pharmacology Research & Perspectives. 2019-09-13 - 11 citationsTargeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.Kate R. Secombe, Imogen A. Ball, Joseph Shirren, Anthony Wignall, John W. Finnie
Cancer Chemotherapy and Pharmacology. 2019-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
